TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28784038

Group type: EXPERIMENTAL
Intervention: Pregabalin 50 mg TDS for 3 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Acetaminophen 500 mg/6 h for 3 days
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 70
Study: 25932840

Group type: EXPERIMENTAL
Intervention: Device-guided slow-paced respiration (n=61)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control device (music-listening group, n=62)
Number of subjects: 123
Study: 23889722

Group type: EXPERIMENTAL
Intervention: Triple-combination treatment with olmesartan medoxomil (OM) 40 mg, amlodipine besylate (AML) 10 mg, and hydrochlorothiazide (HCTZ) 25 mg
Number of subjects: 1555

Group type: EXPERIMENTAL
Intervention: Triple-combination treatment
Number of subjects: 1555

Group type: COMPARATOR
Intervention: Dual-combination treatments
Number of subjects: 1555
Study: 21545395

Group type: EXPERIMENTAL
Intervention: Aerobic training plus resistance training (AT+RT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 30
Study: 19183161

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Number of subjects: 1040
Study: 17680721

Group type: EXPERIMENTAL
Intervention: Vertebral fracture cases
Number of subjects: 80

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 80
Study: 15054353

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (less than 20% energy from fat, five or more fruit/vegetable and six or more grain servings daily)
Number of subjects: 48836

Group type: COMPARATOR
Intervention: Usual diet control
Number of subjects: 48836
Study: 11459901

Group type: EXPERIMENTAL
Intervention: 0.4 g/kg/day IVIg for 3 days
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 0.4 g/kg/day IVIg for 6 days
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (3 days)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (6 days)
Number of subjects: 39
Study: 9732070

Group type: EXPERIMENTAL
Intervention: Double therapy (ZDV + ddC or ddI)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Monotherapy (ZDV)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Patients with baseline CD4+ lymphocyte count >350/microl
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Patients with BVL <10,000 HIV-1 RNA copies/ml
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 169
Study: 1597108

Group type: EXPERIMENTAL
Intervention: Metal endoprostheses (M)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Synthetic endoprostheses (S)
Number of subjects: 58
Study: 4051260

Group type: EXPERIMENTAL
Intervention: Papain (1 mg/mL)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Papain sensitivity
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Chymopapain
Number of subjects: 500
Study: 31286927

Group type: EXPERIMENTAL
Intervention: Diabetes Conversation Map (DCM) education sessions (4 sessions, 40 minutes each over 4 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine Care (RC)
Number of subjects: 120
Study: 29381568

Group type: EXPERIMENTAL
Intervention: Bupivacaine (10 mL) via ultrasound-guided LFC nerve block technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27054751

Group type: EXPERIMENTAL
Intervention: FEC
Number of subjects: 1306

Group type: EXPERIMENTAL
Intervention: EC-DOC
Number of subjects: 1306
Study: 25927297

Group type: EXPERIMENTAL
Intervention: NET (n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NET-R (n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: WL (n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NET and NET-R
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NET-R
Number of subjects: 30
Study: 22621316

Group type: EXPERIMENTAL
Intervention: Ongoing statin + ezetimibe (simvastatin, atorvastatin or pravastatin + ezetimibe at doses of 20/10, 10/10 or 20/10 mg)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Doubling the dose of ongoing statin (simvastatin 40 mg, atorvastatin 20 mg or pravastatin 40 mg)
Number of subjects: 83
Study: 19683989

Group type: EXPERIMENTAL
Intervention: Iloprost infusion initiated 5 days before surgery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Diltiazem infusion before removing the RA
Number of subjects: 70
Study: 17603846

Group type: EXPERIMENTAL
Intervention: 10(6.7) focus‐forming units of the attenuated RIX4414 human rotavirus vaccine
Number of subjects: 319

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study: 15389239

Group type: EXPERIMENTAL
Intervention: IVUS guidance during PCI
Number of subjects: 9069

Group type: COMPARATOR
Intervention: Angiography guidance during PCI
Number of subjects: 9069
Study: 11524061

Group type: EXPERIMENTAL
Intervention: Felodipine-based regimen with additional antihypertensive drugs as needed
Number of subjects: 508

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 508
Study: 9647534

Group type: EXPERIMENTAL
Intervention: Recombinant FSH (Gonal-F) 150 IU
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Recombinant FSH (Gonal-F) 37.5 IU
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Recombinant FSH (Gonal-F) 75 IU
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 8596135

Group type: EXPERIMENTAL
Intervention: rh‐GM‐CSF (5 micrograms/kg s.c. daily for 7 days)
Number of subjects: 11
Study: 2198807

Group type: EXPERIMENTAL
Intervention: Trivalent virus vaccine (measles AIK‐C strain, mumps Hoshino strain, rubella Takahashi strain)
Number of subjects: 1369

Group type: COMPARATOR
Intervention: Monovalent measles vaccine (AIK‐C strain)
Number of subjects: 1369

Group type: COMPARATOR
Intervention: Monovalent mumps vaccine (Hoshino strain)
Number of subjects: 1369
Study: 343726

Group type: EXPERIMENTAL
Intervention: Naproxen (750 mg/day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: COMPARATOR
Intervention: Laboratory assessments
Number of subjects: 9
Study: 31184922

Group type: EXPERIMENTAL
Intervention: mDiab app with weekly coach calls for 12 weeks
Number of subjects: 270

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: mDiab app with video lessons
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: mDiab app
Number of subjects: 270
Study: 28503774

Group type: EXPERIMENTAL
Intervention: DMPA
Number of subjects: 39

Group type: COMPARATOR
Intervention: IUD
Number of subjects: 39
Study: 26667737

Group type: EXPERIMENTAL
Intervention: Exercise program based on balance and lower body strength for 24 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 56
Study: 23127542

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 4

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 4
Study: 21786029

Group type: EXPERIMENTAL
Intervention: Quality management acute pain program (certified by TÜV Rheinland)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Participation in the QUIPS project
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group with no involvement in either concept
Number of subjects: 27
Study: 19199362

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 17147832

Group type: EXPERIMENTAL
Intervention: Tailored energy balance programme for recent retirees, low-intensity, duration of one year.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurements of anthropometry, physical activity, energy intake, and related psychosocial determinants.
Number of subjects: 0
Study: 15331528

Group type: EXPERIMENTAL
Intervention: Insulin (0.1 mU/kg body wt as bolus)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 11546713

Group type: EXPERIMENTAL
Intervention: 0.2 mg x kg(‐1) urapidil
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 0.3 mg x kg(‐1) urapidil
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 0.4 mg x kg(‐1) urapidil
Number of subjects: 150

Group type: COMPARATOR
Intervention: 3 microg x kg(‐1) clonidine (positive control group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: saline 0.9% (negative control group)
Number of subjects: 150
Study: 9100580

Group type: EXPERIMENTAL
Intervention: 100 g glucose (Study 1)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Water (Study 1)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 100 g glucose (Study 2)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Water (Study 2)
Number of subjects: 47
Study: 7794122

Group type: EXPERIMENTAL
Intervention: Warfarin (2-7 mg daily)
Number of subjects: 40
Study: 2968309

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) infusion (125 ng/kg bolus followed by a 30-minute infusion at 25 ng/kg/min)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isotonic saline (time-control)
Number of subjects: 16
Study: 29958220

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.4 µg/kg IV bolus in 10 minutes, followed by 0.5-1.0 µg/kg/h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Remifentanil (0.5 µg/kg IV bolus in 10 minutes, followed by 0.05-0.25 µg/kg/min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 60
Study: 28370407

Group type: EXPERIMENTAL
Intervention: BPS804 (5, 10, and 20 mg/kg, three escalating doses each separated by 2 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Reference group (no treatment)
Number of subjects: 14
Study: 25923596

Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 23171089

Group type: EXPERIMENTAL
Intervention: Capsaicin (0.5mg for FD, 1mg for controls)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Capsaicin
Number of subjects: 34
Study: 22290681

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural block (CSEB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spinal block (SB)
Number of subjects: 40
Study: 19453322

Group type: EXPERIMENTAL
Intervention: i-gel supraglottic airway
Number of subjects: 50

Group type: COMPARATOR
Intervention: classic laryngeal mask airway (cLMA)
Number of subjects: 50
Study: 17078446

Group type: EXPERIMENTAL
Intervention: Acupuncture; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal healthy subjects; control group not explicitly mentioned.
Number of subjects: 0
Study: 15154919

Group type: EXPERIMENTAL
Intervention: Root canal treatment with one of three sealers chosen at random
Number of subjects: 498

Group type: COMPARATOR
Intervention: Conventional success/failure assessment (END2)
Number of subjects: 498
Study: 11316108

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol 2.5 mg with ipratropium 0.5 mg and placebo inhalers (MDI) with spacer
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo nebules and inhaled salbutamol 400 microg with ipratropium 80 microg via MDI with spacer
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol 400 microg with ipratropium 80 microg via MDI with spacer
Number of subjects: 19
Study: 9530619

Group type: EXPERIMENTAL
Intervention: MOM HA (whey hydrolysate formula)
Number of subjects: 25

Group type: COMPARATOR
Intervention: COW (cow's milk)
Number of subjects: 25
Study: 8513853

Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 5 mg b.i.d. isradipine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Co-administration of diclofenac and isradipine
Number of subjects: 18

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 18
Study: 3812056

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (non-smoking)
Number of subjects: 0
Study: 28992127

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 749

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 749
Study: 26603742

Group type: EXPERIMENTAL
Intervention: 1000 mg fast-release aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1000 mg paracetamol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25304478

Group type: EXPERIMENTAL
Intervention: Ungowned
Number of subjects: 214

Group type: COMPARATOR
Intervention: Gowned
Number of subjects: 214
Study: 24189569

Group type: EXPERIMENTAL
Intervention: self-help version of cognitive behavioral therapy (shCBT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: usual care (UC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: shCBT
Number of subjects: 48

Group type: COMPARATOR
Intervention: UC
Number of subjects: 48
Study: 21393063

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 1.5 g/day for 24 months
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 277
Study: 18443265

Group type: EXPERIMENTAL
Intervention: Active normal-weight individuals
Number of subjects: 38987

Group type: EXPERIMENTAL
Intervention: Increasing levels of walking
Number of subjects: 38987
Study: 17194233

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg.kg(‐1))
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12707479

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy plus routine care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 0
Study: 11028832

Group type: EXPERIMENTAL
Intervention: 5 mg tropisetron
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: 10 mg tropisetron
Number of subjects: 418

Group type: COMPARATOR
Intervention: 15 mg tropisetron
Number of subjects: 418

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study: 8864090

Group type: EXPERIMENTAL
Intervention: Laparoscopic herniorrhaphy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Open tension-free Lichtenstein repair
Number of subjects: 53
Study: 2056905

Group type: EXPERIMENTAL
Intervention: Caffeine citrate (CC) 7.0 mg of anhydrous caffeine.kg‐1 body weight
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 10
Study: 7171533

Group type: EXPERIMENTAL
Intervention: High-methoxyl pectin (15 g)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-methoxyl pectin (15 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no pectin)
Number of subjects: 10
Study: 29794847

Group type: EXPERIMENTAL
Intervention: ROTEM
Number of subjects: 2287

Group type: EXPERIMENTAL
Intervention: TEG
Number of subjects: 2287

Group type: EXPERIMENTAL
Intervention: EXTEM-FIBTEM
Number of subjects: 2287

Group type: EXPERIMENTAL
Intervention: rTEG-FF
Number of subjects: 2287

Group type: EXPERIMENTAL
Intervention: EXTEM
Number of subjects: 2287

Group type: EXPERIMENTAL
Intervention: rTEG
Number of subjects: 2287

Group type: EXPERIMENTAL
Intervention: EXTEM Li30
Number of subjects: 2287

Group type: EXPERIMENTAL
Intervention: rTEG Ly30
Number of subjects: 2287
Study: 28010246

Group type: EXPERIMENTAL
Intervention: Monovalent rAT or rLukS-PV dosages of 10, 25, 50, and 100 μg; bivalent rAT:rLukS dosages of 10:10, 25:25, and 50:50 μg; alum or saline placebo
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Monovalent and bivalent rAT dosages
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: 50 μg monovalent or bivalent rAT and rLukS-PV dose
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Second dose of the vaccine
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo (alum or saline)
Number of subjects: 176
Study: 25005011

Group type: EXPERIMENTAL
Intervention: SILS training curriculum
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SILS training curriculum (group A, tested after 4 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SILS training curriculum (group B, tested after 12 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of group A and group B
Number of subjects: 30
Study: 24508897

Group type: EXPERIMENTAL
Intervention: 40 mg of tenofovir alafenamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 120 mg of tenofovir alafenamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: 300 mg of tenofovir disoproxil fumarate
Number of subjects: 0
Study: 22020082

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 19758519

Group type: EXPERIMENTAL
Intervention: STEP-BD study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bipolar Trials Network (BTN)
Number of subjects: 0
Study: 17827369

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 27
Study: 15042669

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (paclitaxel followed by combined 5-fluorouracil, doxorubicin, and cyclophosphamide)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Primary surgical management (control group)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 240
Study: 11180038

Group type: EXPERIMENTAL
Intervention: Everolimus 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone
Number of subjects: 101

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 101
Study: 9621991

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroid therapy (ACT) with dexamethasone
Number of subjects: 103

Group type: COMPARATOR
Intervention: Non-ACT group (no antenatal corticosteroid therapy)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment of the mother
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Tocolytic treatment of the mother
Number of subjects: 103
Study: 8165968

Group type: EXPERIMENTAL
Intervention: Silicone intraocular lens implantation through a 3.2 mm incision
Number of subjects: 150

Group type: COMPARATOR
Intervention: Polymethylmethacrylate intraocular lens implantation through a 5.5 mm incision
Number of subjects: 150
Study: 3357663

Group type: EXPERIMENTAL
Intervention: Intraumbilical oxytocin (10 U diluted to 20 mL in normal saline)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline (20 mL)
Number of subjects: 50
Study: 29807936

Group type: EXPERIMENTAL
Intervention: Community Paramedicine at Clinic (CP@clinic) for 1 year
Number of subjects: 1092

Group type: COMPARATOR
Intervention: Usual health care
Number of subjects: 1092
Study: 27911016

Group type: EXPERIMENTAL
Intervention: omalizumab 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: omalizumab (75, 150 or 300 mg)
Number of subjects: 0
Study: 26720473

Group type: EXPERIMENTAL
Intervention: Customized heterochromatic flicker photometry (Densitometer)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Dual-wavelength fundus autofluorescence (Spectralis)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Both devices (Densitometer and Spectralis)
Number of subjects: 117
Study: 23398390

Group type: EXPERIMENTAL
Intervention: Intervention group (smoking cessation programme)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 161
Study: 21509050

Group type: EXPERIMENTAL
Intervention: Waist circumference (WC) at baseline
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Change in waist circumference (WC) from baseline to follow-up
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) at baseline
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Change in body mass index (BMI) from baseline to follow-up
Number of subjects: 1675
Study: 19090310

Group type: EXPERIMENTAL
Intervention: Placement of alkalinized lidocaine into the ETT cuff at intubation
Number of subjects: 160

Group type: COMPARATOR
Intervention: Injection of local anesthetic into the LITA tube
Number of subjects: 160
Study: 16773350

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 12818462

Group type: EXPERIMENTAL
Intervention: Low dose hormone replacement therapy (LD‐HRT) with conjugated equine estrogens (CEE; 0.3 mg) and different progestins (2.5 mg medroxyprogesterone acetate, 5 mg dydrogesterone, 2.5 mg nomegestrol)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Calcium supplementation (1 g per day)
Number of subjects: 63
Study: 10969300

Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg/kg) administered 5 min before surgery
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg/kg) administered 10 min before surgery
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg/kg) administered 20 min before surgery
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo administered 15 min before surgery
Number of subjects: 113
Study: 8725758

Group type: EXPERIMENTAL
Intervention: Hysteroscopic endometrial resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transabdominal hysterectomy
Number of subjects: 0
Study: 14621765

Group type: EXPERIMENTAL
Intervention: BT 563 (new monoclonal IL-2R antibody)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ATG (historical control)
Number of subjects: 0
Study: 3881920

Group type: EXPERIMENTAL
Intervention: 10 cm H2O of CPAP
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ambient airway pressure breathing (Control)
Number of subjects: 40
Study: 30869649

Group type: EXPERIMENTAL
Intervention: Health‐E You app (mHealth intervention)
Number of subjects: 18
Study: 27599712

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) techniques
Number of subjects: 8
Study: 26355978

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac (0.5 mg/kg) and acetaminophen (15 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral ibuprofen (10 mg/kg) and acetaminophen (15 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral ibuprofen and acetaminophen
Number of subjects: 50
Study: 24028669

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 1577

Group type: COMPARATOR
Intervention: Comparators
Number of subjects: 1577
Study: 20923377

Group type: EXPERIMENTAL
Intervention: Wire-guided cannulation (WGC)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Standard cannulation method (STD)
Number of subjects: 172
Study: 19811166

Group type: EXPERIMENTAL
Intervention: Computer Assisted Learning (CAL) group
Number of subjects: 85

Group type: COMPARATOR
Intervention: Lecture group
Number of subjects: 85
Study: 16849414

Group type: EXPERIMENTAL
Intervention: DHEA (50 mg)
Number of subjects: 51
Study: 14663318

Group type: EXPERIMENTAL
Intervention: Tc‐99m HMPAO WBC imaging
Number of subjects: 34